

# Local Coverage Article: Billing and Coding: MoIDX: CYP2C9 and/or VKORC1 Gene Testing for Warfarin Response (A55180)

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.

## Contractor Information

CONTRACTOR NAME	CONTRACT TYPE	CONTRACT NUMBER	JURISDICTION	STATE(S)
Noridian Healthcare Solutions, LLC	A and B MAC	02101 - MAC A	J - F	Alaska
Noridian Healthcare Solutions, LLC	A and B MAC	02102 - MAC B	J - F	Alaska
Noridian Healthcare Solutions, LLC	A and B MAC	02201 - MAC A	J - F	Idaho
Noridian Healthcare Solutions, LLC	A and B MAC	02202 - MAC B	J - F	Idaho
Noridian Healthcare Solutions, LLC	A and B MAC	02301 - MAC A	J - F	Oregon
Noridian Healthcare Solutions, LLC	A and B MAC	02302 - MAC B	J - F	Oregon
Noridian Healthcare Solutions, LLC	A and B MAC	02401 - MAC A	J - F	Washington
Noridian Healthcare Solutions, LLC	A and B MAC	02402 - MAC B	J - F	Washington
Noridian Healthcare Solutions, LLC	A and B MAC	03101 - MAC A	J - F	Arizona
Noridian Healthcare Solutions, LLC	A and B MAC	03102 - MAC B	J - F	Arizona
Noridian Healthcare Solutions, LLC	A and B MAC	03201 - MAC A	J - F	Montana
Noridian Healthcare Solutions, LLC	A and B MAC	03202 - MAC B	J - F	Montana
Noridian Healthcare Solutions, LLC	A and B MAC	03301 - MAC A	J - F	North Dakota
Noridian Healthcare Solutions, LLC	A and B MAC	03302 - MAC B	J - F	North Dakota
Noridian Healthcare Solutions, LLC	A and B MAC	03401 - MAC A	J - F	South Dakota
Noridian Healthcare Solutions, LLC	A and B MAC	03402 - MAC B	J - F	South Dakota
Noridian Healthcare Solutions, LLC	A and B MAC	03501 - MAC A	J - F	Utah
Noridian Healthcare Solutions, LLC	A and B MAC	03502 - MAC B	J - F	Utah
Noridian Healthcare Solutions, LLC	A and B MAC	03601 - MAC A	J - F	Wyoming
Noridian Healthcare Solutions, LLC	A and B MAC	03602 - MAC B	J - F	Wyoming

## Article Information

### General Information

**Article ID**

A55180

**Original Effective Date**

10/24/2016

**Article Title**

Billing and Coding: MoIDX: CYP2C9 and/or VKORC1  
Gene Testing for Warfarin Response

**Revision Effective Date**

12/12/2019

**Article Type**

Billing and Coding

**Revision Ending Date**

N/A

**AMA CPT / ADA CDT / AHA NUBC Copyright Statement**

CPT codes, descriptions and other data only are copyright 2019 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.

**Retirement Date**

N/A

Current Dental Terminology © 2019 American Dental Association. All rights reserved.

Copyright © 2020, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB-04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312-893-6816. Making copies or utilizing the content of the UB-04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB-04 Manual and/or codes and descriptions; and/or making any commercial use of UB-04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. To license the electronic data file of UB-04 Data Specifications, contact Tim Carlson at (312) 893-6816 or Laryssa Marshall at (312) 893-6814. You may also contact us at [ub04@healthforum.com](mailto:ub04@healthforum.com).

**CMS National Coverage Policy**

CMS IOM Publication 100-04, *Medicare Claims Processing* CR 6715, Pharmacogenomic Testing for Warfarin Response

**Article Guidance****Article Text:**

Based on NCD 90.1 - Pharmacogenomic Testing for Warfarin Response, gene testing on CYP2C9 and/or VKORC1 will only be covered through coverage with evidence development (CED). Testing will be limited to once in a lifetime per beneficiary. MoIDX will reimburse ONLY genetic testing services for beneficiaries who meet the NCD criteria and are enrolled in a clinical trial.

Lab providers that perform services on eligible beneficiaries and described by CPT codes 81227 and 81355 must submit the following claim items:

- **HCPCS code:** G9143- warfarin responsiveness testing
- **ICD-10-CM code:** Z00.6-Encounter for examination for normal comparison and control in clinical research program
- **HCPCS modifier QO** - Investigational clinical service provided in a clinical research study that is in an approved clinical research study
- Enter the appropriate DEX Z-Code™ identifier adjacent to the CPT® code in the comment/narrative field for the following claim field/types:
  - Loop 2400 or SV101-7 for the 5010A1 837P
  - Item 19 for paper claim
  
- Enter the appropriate DEX Z-Code™ identifier adjacent to the CPT® code in the comment/narrative filed for the following Part A claim field/types:
  - Line SV202-7 for 837I electronic claim
  - Block 80 for the UB04 claim form

**Note:**

1. Report only G9143 and 1 UOS. Do NOT report 81227 and/or 81355 on the claim
2. Report only 1 ID on the claim
3. To facilitate payment, please add the voluntarily reported 8-digit clinical trial number

**References:**

Publication 100-04, Medicare Claims Processing  
CR#6715  
NCD 90.1 - Pharmacogenomic Testing for Warfarin Response

---

## Coding Information

**CPT/HCPCS Codes**

**Group 1 Paragraph:**

For warfarin response pharmacogenomics testing the following HCPCS code should be used and reported as a single unit of service regardless of how many genes are analyzed or which genes are analyzed.

**Group 1 Codes:**

CODE	DESCRIPTION
G9143	WARFARIN RESPONSIVENESS TESTING BY GENETIC TECHNIQUE USING ANY METHOD, ANY NUMBER OF SPECIMEN(S)

**Group 2 Paragraph:**

The following codes should not be used to report pharmacogenomic testing for warfarin response, regardless of whether the test assesses CYP2C9 and/or VKORC.

**Group 2 Codes:**

CODE	DESCRIPTION
81227	CYP2C9 (CYTOCHROME P450, FAMILY 2, SUBFAMILY C, POLYPEPTIDE 9) (EG, DRUG METABOLISM), GENE ANALYSIS, COMMON VARIANTS (EG, *2, *3, *5, *6)
81355	VKORC1 (VITAMIN K EPOXIDE REDUCTASE COMPLEX, SUBUNIT 1) (EG, WARFARIN METABOLISM), GENE ANALYSIS, COMMON VARIANT(S) (EG, -1639G>A, C.173+1000C>T)

**CPT/HCPCS Modifiers****Group 1 Paragraph:**

N/A

**Group 1 Codes:**

CODE	DESCRIPTION
Q0	INVESTIGATIONAL CLINICAL SERVICE PROVIDED IN A CLINICAL RESEARCH STUDY THAT IS IN AN APPROVED CLINICAL RESEARCH STUDY

**ICD-10 Codes that Support Medical Necessity****Group 1 Paragraph:**

N/A

**Group 1 Codes:**

ICD-10 CODE	DESCRIPTION
Z00.6	Encounter for examination for normal comparison and control in clinical research program

**ICD-10 Codes that DO NOT Support Medical Necessity**

N/A

### Additional ICD-10 Information

N/A

### Bill Type Codes:

Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the policy does not apply to that Bill Type. Complete absence of all Bill Types indicates that coverage is not influenced by Bill Type and the policy should be assumed to apply equally to all claims.

N/A

### Revenue Codes:

Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory. Unless specified in the policy, services reported under other Revenue Codes are equally subject to this coverage determination. Complete absence of all Revenue Codes indicates that coverage is not influenced by Revenue Code and the policy should be assumed to apply equally to all Revenue Codes.

N/A

### Other Coding Information

N/A

## Revision History Information

REVISION HISTORY DATE	REVISION HISTORY NUMBER	REVISION HISTORY EXPLANATION
12/12/2019	R1	Revised CMS references. Added Part A claim filing information. Under <b>CPT/HCPCS Codes Group 1: Paragraph</b> added the verbiage "For warfarin response pharmacogenomics testing the following HCPCS code should be used and reported as a single unit of service regardless of how many genes are analyzed or which genes are analyzed." Added <b>CPT/HCPCS Codes Group 2: 81227 and 81355</b> and the verbiage "The following codes should not be used to report pharmacogenomic testing for warfarin response, regardless of whether the test assesses CYP2C9 and / or VKORC." Under <b>CPT/HCPCS Modifiers Group 1: Codes</b> added modifier Q0.

## Associated Documents

### Related Local Coverage Document(s)

LCD(s)

L36312 - MoIDX: CYP2C19, CYP2D6, CYP2C9, and VKORC1 Genetic Testing

**Related National Coverage Document(s)**

N/A

**Statutory Requirements URL(s)**

N/A

**Rules and Regulations URL(s)**

N/A

**CMS Manual Explanations URL(s)**

N/A

**Other URL(s)**

N/A

**Public Version(s)**

Updated on 12/08/2019 with effective dates 12/12/2019 - N/A

Updated on 08/12/2016 with effective dates 10/24/2016 - N/A

---

## Keywords

- MoIDX
- CYP2C9
- VKORC1
- G9143
- 81227
- 81355